Novartis

View All

recent-pharma-news-and-updates-for-novartis-gsk-exact-sciences-eqrx
Novartis taps Molecular Partners to combat COVID-19; GSK culls phase 2 asthma drug; Exact Sciences acquires Thrive for $ 2.15 B; EQRx-CStone’s deal for checkpoint inhibitors

Novartis taps Molecular Partners for a novel approach to combat COVID-19 Novartis is spending USD 69 million upfront on a pair of experimental drugs from Molecular Partners. The pact is for MP0420 and MP0423, two antivirals out of the biotech’s so-called DARPin tech, which Molecular Partners says that it has ...

Find More

Pharma news for Bayer, Novartis, Forma, AskBio
Bayer eyes AskBio’s Gene Therapies; Novartis’ Iptacopan; Forma’s IDH1-Mutated AML Therapy; EpicGenetics teams up with Mayo Clinic

Bayer Set to Fork Over USD 4 Billion for AskBio’s Gene Therapies Germany-based Bayer is set to acquire North Carolina-based Asklepios BioPharmaceutical (AskBio) with motives to get its hands on its gene therapies.  Bayer will pay USD 2 billion in upfront payment in exchange for AskBio's AAV-based gene th...

Find More

spartalizumab failure
Novartis’s Spartalizumab Combo Stumbles; Union Therapeutics Doses In COVID-19 Trial; Yumanity To Merge With Proteostasis

Novartis’s Spartalizumab Combo Fails To Meet The Primary Goal In The Melanoma Trial  Novartis recently declared the results of its Phase III COMBI-I trial evaluating its experimental checkpoint inhibitor spartalizumab in combination with Tafinlar (dabrafenib) and Mekinist (trametinib) for patients, previous...

Find More

Latest pharma happenings for Roche and Secura Bio
FDA’s Ok to Roche’s Oral SMA Therapy; Roche’s Etrolizumab Mixed Results in Ulcerative Colitis; Secura receives rights to Copiktra from Verastem

Roche Set to Compete With Biogen and Novartis in the SMA Market With its First Oral Therapy  The US FDA has recommended the use of Evrysdi (risdiplam), a candidate of Genentech, a Roche company, for spinal muscular atrophy (SMA), an inherited neuromuscular disease resulting in muscle atrophy, in adults and...

Find More

Top-cancers-in-the-world
Top 5 Cancers Creating Major Challenge To The Global Healthcare System

Over the past few decades Cancer has emerged as a major public health concern worldwide. Cancer is the second leading cause of deaths that takes place worldwide. Every sixth death is due to cancer, and in 2018 was estimated to be responsible for 9.6 million deaths. Costing people quality of lives and eventually lea...

Find More

Alzheimer’s Disease Market | Biogen | Aducanumab | Eisai| Biogen | Aducanumab | Eisai |
Can Aducanumab Solve the Puzzle Of Alzheimer’s?

Alzheimer's Disease Market finally witnessed the approval of standard therapy, Aducanumab, by Biogen. What impact does it hold for the future? Demographic or population ageing is a global and dominant phenomenon of the 21st century. Different geographies are experiencing population ageing at different rates. As ...

Find More

Prostate Cancer Market
Prostate Cancer Market Experiences an Influx of the Pharma Players Veering the Market Ahead

Prostate Cancer Market Size is Expected to Increase with a CAGR of 8.1% in the 7MM for the study period of 2017-30 owing to rich Pipeline, Increasing Awareness and Better Treatment Options. A malignancy of prostate glands, Prostate Cancer, develops slowly and remains confined to prostate glands, however, can inv...

Find More

Alzheimer’s-Disease-Market-Scenario
An Ageing Population and Upcoming Therapies: What is shaping the Alzheimer’s Disease Market Scenario?

The ageing population is a global phenomenon. According to the UN’s “World Population Prospects 2019” by 2100, the world’s population is projected to reach approximately 10.9 billion. Moreover, between 2020 and 2100, the number of people ages 80 and older is expected to increase from 146 million to 881 million. ...

Find More

pharma-news
Startup focuses tumors with CAR-T; AbCellera grabs USD 105M; Gilead inks USD 2B deal; GSK’s anti-BCMA antibody receives a boost

The startup focuses on glioblastoma tumors with CAR-T therapy. CAR-T technology that involves genetically modifying a patient’s immune cells to recognize and attack cancer. However, while the innovation has helped patients with certain blood malignancies, progress in solid tumors remains restricted. The scien...

Find More

pharma-news
Merck supports Peloton Therapeutics; Thermo Fisher, WuXi and Mayo Clinic join hands; JNJ’s anti-BCMA CAR-T sweeps multiple myeloma aside; Tafinlar-Mekinist combo of Novartis receives a boost

Merck supports Peloton Therapeutics with positive kidney cancer data Merck is revealing the data from a phase 2 study of a HIF-2α inhibitor after a year betting USD 1.05 billion on Peloton Therapeutics, and the deal is promising.  The drug limited tumour growth in 43% and shrank tumors in 28% of patients...

Find More